Kristeleit RS, Ghamande S, Lisyanskaya A, Oaknin A, et al. Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45. Ann Oncol 2025 Oct 18:S0923-7534(25)04950-6. doi: 10.1016/j.annonc.2025.
PMID: 41115469